DIVP - ETF AI Analysis
Top Page
Cullen Enhanced Equity Income ETF (DIVP)
DIVP, the Cullen Enhanced Equity Income ETF, appears to be a solid, quality fund supported by strong, diversified holdings in healthcare, energy, and technology. Standout positions like Medtronic and Merck contribute positively through robust financial performance, innovation, and attractive income features, while IBM adds strength with its focus on AI and hybrid cloud despite some valuation concerns. The main risk factor is the fund’s notable exposure to large energy names such as EOG, ConocoPhillips, and Exxon Mobil, which can increase sensitivity to commodity price swings and sector-specific volatility.
DIVP vs. SPDR S&P 500 ETF (SPY)
- AUM
- 62.86M
- Region
- North America
- Expense Ratio
- 0.55%
- Beta
- 0.41
- Issuer
- Cullen
- Inception Date
- Mar 06, 2024
- Dividend Yield
- 5.81%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
DIVP Summary
DIVP, the Cullen Enhanced Equity Income ETF, invests across the broad U.S. stock market with a focus on both growth and steady income rather than tracking a specific index. It holds a mix of sectors like health care, financials, energy, and consumer companies, including well-known names such as UnitedHealth, IBM, Merck, and ConocoPhillips. This ETF may appeal to investors who want diversification plus potential dividend income from established businesses. However, like any stock-based fund, its value can go up and down with the overall market, and income payments are not guaranteed.
How much will it cost me?
This ETF has an expense ratio of 0.55%, which means you’ll pay about $5.50 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because DIVP is actively managed, with professionals selecting and adjusting the portfolio to pursue enhanced equity income.
What would affect this ETF?
DIVP could benefit if the U.S. economy stays stable, healthcare demand remains strong, and energy prices support profits for its large health care and energy holdings like UnitedHealth and EOG Resources, while its income-focused strategy may be helped by steady or falling interest rates. On the downside, higher interest rates, tighter regulations on health care or energy, or a broad U.S. market downturn could hurt both the value of its diversified stock portfolio and the income it aims to generate.
DIVP Top 10 Holdings
DIVP is leaning heavily on U.S. health care and energy names, with Merck and UnitedHealth acting as steady engines while Bristol-Myers has been more mixed and occasionally losing steam. On the energy side, ConocoPhillips and EOG Resources are clearly rising, giving the fund a strong tailwind. Qualcomm adds a touch of tech momentum, though its run has been a bit choppy, and IBM’s recent weakness has slightly dragged on returns. Overall, the ETF is U.S.-centric, diversified but with a noticeable tilt toward defensive health care and cash-generating energy plays.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 EOG | EOG Resources | 4.45% | $2.80M | $86.83B | 56.97% | 78Outperform |
 COP | Conocophillips | 4.34% | $2.74M | $185.04B | 74.76% | 78Outperform |
 UNH | UnitedHealth | 3.86% | $2.43M | $365.29B | 18.05% | 72Outperform |
 BDX | Becton Dickinson | 3.76% | $2.37M | $53.90B | 10.31% | 67Neutral |
 MDT | Medtronic | 3.59% | $2.26M | $123.49B | 6.12% | 80Outperform |
 IBM | International Business Machines | 3.58% | $2.26M | $243.66B | -16.85% | 79Outperform |
 SYY | Sysco | 3.51% | $2.21M | $40.78B | 10.98% | 71Outperform |
 MRK | Merck & Company | 3.29% | $2.07M | $368.89B | 73.30% | 80Outperform |
 BMY | Bristol-Myers Squibb | 3.23% | $2.03M | $127.71B | 36.96% | 78Outperform |
 QCOM | Qualcomm | 3.04% | $1.91M | $175.97B | -7.03% | 80Outperform |
DIVP Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DIVP, the sentiment is Positive. The current price of 27.61 is above the 20-day moving average (MA) of 26.74, above the 50-day MA of 26.81, and above the 200-day MA of 26.14, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 67.75 is Neutral, neither overbought nor oversold. The STOCH value of 78.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DIVP.
DIVP Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| DIVP | $27.61 | $29.00(5.02% Upside) | $62.86M | 0.55% | 69Neutral |
 STNC | $37.32 | $42.63(14.24% Upside) | $93.14M | 0.85% | 68Neutral |
 SOVF | $31.63 | $37.40(18.24% Upside) | $90.20M | 0.75% | 70Neutral |
 PFOE | $21.63 | $29.13(34.68% Upside) | $88.71M | 0.59% | 75Outperform |
 VAMO | $36.31 | $42.56(17.21% Upside) | $87.92M | 0.65% | 63Neutral |
 RFDA | $73.15 | $82.46(12.73% Upside) | $79.16M | 0.52% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DIVP | Cullen Enhanced Equity Income ETF | 27.61 | 4.75 | 20.75% | |
| STNC | Stance Equity ESG Large Cap Core ETF | 37.32 | 5.00 | 15.49% | |
| SOVF | Sovereign's Capital Flourish Fund | 31.63 | 3.21 | 11.29% | |
| PFOE | Pathfinder Focused Opportunities ETF | 21.63 | -3.23 | -13.00% | |
| VAMO | Cambria Value & Momentum ETF | 36.31 | 3.71 | 11.37% | |
| RFDA | RiverFront Dynamic US Dividend Advantage ETF | 73.15 | 10.80 | 17.32% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.